EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)

Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial

Tianshu Liu, Suxia Luo, Xianglin Yuan, Dong Liu, Zhaofei Zhou, Xin Wang, Yanhong Deng iD, Jun Chen, Mulin Liu, Huan Zhou, Xiubao Ren iD, Wensheng Qiu iD und 13 weitere

Journal of Clinical Oncology · 01.05.2026 · 44 (13) · 1225-1237

DOI: 10.1200/jco-25-00716 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.05.2026. Verfasst von Tianshu Liu und 24 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Trastuzumab, Esophagogastric Junction, Colorectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2) could be a promising strategy for HER2-expressing gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJ) and colorectal cancer (CRC). We conducted a phase I trial to assess trastuzumab rezetecan, a novel HER2-targeted ADC, in HER2-expressing advanced GC/GEJ and CRC. METHODS Patients with HER2-expressing advanced GC/GEJ and CRC whose disease progressed on and/or had no available/applicable standard treatment were enrolled. Patients were intravenously given trastuzumab rezetecan at 3.2, 4.8, 6.4, and 8.0 mg/kg (once every 3 weeks) in an i3+3 dose-escalation scheme, followed by pharmacokinetics expansion at selected doses and then clinical expansion. The primary end points were dose-limiting toxicity (DLT) and safety. RESULTS Between March 30, 2021, and August 1, 2023, 100 patients were enrolled (57 with GC/GEJ and 43 with CRC). One DLT occurred in the 8.0 mg/kg dose cohort. Grade ≥3 treatment-related adverse events (TRAEs) were reported in 66 (66.0%) patients. Only 5 (5.0%) patients discontinued treatment because of TRAEs. In HER2-positive GC/GEJ (n = 40), trastuzumab rezetecan achieved an objective response rate (ORR) of 45.0%, a median progression-free survival (PFS) of 9.0 months (95% CI, 7.0 to 11.3), and a median overall survival (OS) of 16.3 months (95% CI, 12.4 to not reached [NR]). In GC/GEJ with HER2 immunohistochemical 2+ and in situ hybridization–negative (n = 12), trastuzumab rezetecan had an ORR of 25.0%, a median PFS of 12.2 months (95% CI, 2.8 to 14.0), and an immature median OS. In HER2-positive CRC (n = 37), trastuzumab rezetecan had an ORR of 40.5%, a median PFS of 9.5 months (95% CI, 7.3 to 11.2), and a median OS of 22.7 months (95% CI, 17.5 to NR). CONCLUSION Trastuzumab rezetecan showed tolerable safety and preliminary efficacy in HER2-expressing advanced GC/GEJ and CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsTrastuzumabEsophagogastric JunctionColorectal NeoplasmsErb-b2 Receptor Tyrosine KinasesAdenocarcinomaImmunoconjugatesAntibodies, Monoclonal, HumanizedEsophageal NeoplasmsAntineoplastic Agents, ImmunologicalHumansFemaleMiddle AgedAgedMaleAdultAged, 80 and overCamptothecin

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanImmunoconjugatestrastuzumab deruxtecanAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCamptothecin

Autor:innen und Institutionen

  • Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Phase I Clinical Research Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Department of Digestive Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.
  • Department of GCP, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.

ORCID-Profile: Yanhong Deng, Xiubao Ren, Wensheng Qiu, Heli Liu, Jin Li

Zitieren

APA

Liu, T., Luo, S., Yuan, X., Liu, D., Zhou, Z., Wang, X., Deng, Y., Chen, J., Liu, M., Zhou, H., Ren, X., Qiu, W., Cao, Y., Cai, S., Dong, Y., Zhang, Y., Wang, W., Liang, J., Xu, P., …, & Li, J. (2026). Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. Journal of Clinical Oncology, 44(13), 1225-1237. https://doi.org/10.1200/jco-25-00716

Vancouver

Liu T, Luo S, Yuan X, Liu D, Zhou Z, Wang X, et al. Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. Journal of Clinical Oncology. 2026;44(13):1225-1237. doi:10.1200/jco-25-00716

BibTeX
@article{Liu2026,
  author = {Liu, Tianshu and Luo, Suxia and Yuan, Xianglin and Liu, Dong and Zhou, Zhaofei and Wang, Xin and Deng, Yanhong and Chen, Jun and Liu, Mulin and Zhou, Huan and Ren, Xiubao and Qiu, Wensheng and Cao, Yu and Cai, Shirong and Dong, Yugang and Zhang, Yanqiao and Wang, Wei and Liang, Jun and Xu, Pingsheng and Liu, Heli and Zhao, Kaijing and Fan, Yang and Dou, Ning and Huang, Chuanpei and Li, Jin},
  title = {Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {13},
  pages = {1225--1237},
  doi = {10.1200/jco-25-00716}
}
Kostenlos starten →